Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans
Sponsor: Sarcoma Alliance for Research through Collaboration
Listed as NCT00243191, this PHASE2 trial focuses on Dermatofibrosarcoma Protuberans and remains completed. Sponsored by Sarcoma Alliance for Research through Collaboration, it has been updated 8 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
May 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sarcoma Alliance for Research through Collaboration
For direct contact, visit the study record on ClinicalTrials.gov .